+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Bronchitis Drugs Market 2018-2022 - Product Image

Global Bronchitis Drugs Market 2018-2022

  • ID: 4744683
  • Report
  • Region: Global
  • 106 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Sanofi
  • MORE
For bettering the public understanding of the disease, many government as well as non-government agencies are taking initiatives to improve public awareness of bronchitis. Many organizations suggest not to treat acute bronchitis with antibiotics, as such drugs are not indicated for diseases like acute bronchitis. Moreover, there are a few not-for-profit foundations on asthma and other respiratory illnesses, such as the Asthma Foundation, which offer support to patients.

Asthma Foundation focuses on increasing the awareness of respiratory illnesses, funds research for better treatments, and provides education on best practices. Such initiatives for generating awareness of bronchitis among patients and physicians will result in better diagnosis of bronchitis and help in the global market's growth. The analysts have predicted that the bronchitis drugs market will register a CAGR of close to 4% by 2022.

Market Overview

Strong pipeline

Bronchitis treatment has a strong pipeline due to the extensive R&D in this field. Currently, the bronchitis treatment pipeline has around 6 trials in phase I, phase II, and phase III, in which 3 are in phase III. There are a few promising molecules in the pipeline for indications such as acute and chronic bronchitis.

High economics burden of bronchitis

Incomplete or inaccurate diagnosing of chronic bronchitis can have a substantial impact on healthcare costs, resulting in a higher economic burden for people with the disease.

For the detailed list of factors that will drive and challenge the growth of the bronchitis drugs market during the 2018-2022, view this report.

Competitive Landscape

The bronchitis drugs market is moderately fragmented with the presence of several bronchitis drug manufacturers. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Bronchitis pipeline
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: SEGMENTATION BY DRUG TYPE
  • Antibiotics
  • Anti-inflammatory drugs
  • Bronchodilators
  • Mucolytics
PART 09: MARKET SEGMENTATION BY APPLICATION
  • Segmentation by application
  • Comparison by application
  • Acute bronchitis - Market size and forecast 2017-2022
  • Chronic bronchitis - Market size and forecast 2017-2022
Market opportunity by application

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • EMEA - Market size and forecast 2017-2022
  • Americas - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • High use of antibiotics for bronchitis treatment
  • Use of off-label drugs for bronchitis
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Sanofi
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global respiratory drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs for bronchitis 2017-2018
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global bronchitis drugs market - Market size and forecast 2017-2022 ($ bn)
Exhibit 10: Global bronchitis drugs market - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition - Five forces 2017
Exhibit 19: LABAs with their respective time of onset of action and duration of action
Exhibit 20: Global bronchitis drugs market by application - Market share 2017-2022 (%)
Exhibit 21: Comparison by application
Exhibit 22: Acute bronchitis - Market size and forecast 2017-2022 ($ bn)
Exhibit 23: Acute bronchitis - Year-over-year growth 2018-2022 (%)
Exhibit 24: US FDA-approved LABAs and LAMAs FDC
Exhibit 25: Chronic bronchitis - Market size and forecast 2017-2022 ($ bn)
Exhibit 26: Chronic bronchitis - Year-over-year growth 2018-2022 (%)
Exhibit 27: Market opportunity by application
Exhibit 28: Customer landscape
Exhibit 29: Global bronchitis drugs market by geography - Market share 2017-2022 (%)
Exhibit 30: Regional comparison
Exhibit 31: EMEA - Market size and forecast 2017-2022 ($ bn)
Exhibit 32: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: Americas - Market size and forecast 2017-2022 ($ bn)
Exhibit 35: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 36: Top 3 countries in Americas
Exhibit 37: APAC - Market size and forecast 2017-2022 ($ bn)
Exhibit 38: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 39: Top 3 countries in APAC
Exhibit 40: Market opportunity
Exhibit 41: Late-stage pipeline drugs for bronchitis 2017-2018
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: AstraZeneca: An overview
Exhibit 48: AstraZeneca - Business segments
Exhibit 49: AstraZeneca - Organizational developments
Exhibit 50: AstraZeneca - Geographic focus
Exhibit 51: AstraZeneca - Key offerings
Exhibit 52: GlaxoSmithKline: An overview
Exhibit 53: GlaxoSmithKline - Business segments
Exhibit 54: GlaxoSmithKline - Organizational developments
Exhibit 55: GlaxoSmithKline - Geographic focus
Exhibit 56: GlaxoSmithKline - Segment focus
Exhibit 57: GlaxoSmithKline - Key offerings
Exhibit 58: Novartis: An overview
Exhibit 59: Novartis - Business segments
Exhibit 60: Novartis - Organizational developments
Exhibit 61: Novartis - Geographic focus
Exhibit 62: Novartis - Segment focus
Exhibit 63: Novartis - Key offerings
Exhibit 64: Sanofi: An overview
Exhibit 65: Sanofi - Business segments
Exhibit 66: Sanofi - Organizational developments
Exhibit 67: Sanofi - Geographic focus
Exhibit 68: Sanofi - Segment focus
Exhibit 69: Sanofi- Key offerings
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Sanofi
  • MORE
Global Bronchitis Drugs Market 2018-2022

The analyst recognizes the following companies as the key players in the global bronchitis drugs market: AstraZeneca, GlaxoSmithKline, Novartis, Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the trend of excessive use of antibiotics for the treatment of bronchitis is expected to negatively impact the global market.”

According to the report, one of the major drivers for this market is the initiatives for generating awareness of bronchitis among patients and physicians will result in better diagnosis of bronchitis and help in the global market's growth.

Further, the report states that one of the major factors hindering the growth of this market is the use of conventional protocols and devices for diagnosis is expected to restrict the growth of the global bronchitis drugs market.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • AstraZeneca
  • GlaxoSmithKline
  • Novartis
  • Sanofi
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4744683
Adroll
adroll